Skip to content

Effectiveness and Safety of Superselective Adrenal Artery Embolization in the Treatment of Primary Adosteronism

Effectiveness and Safety of Superselective Adrenal Artery Embolization in the Treatment of Primary Adosteronism

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045896
Enrollment
Unknown
Registered
2021-04-27
Start date
2021-04-21
Completion date
Unknown
Last updated
2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Adosteronism

Interventions

single arm:Superselective Adrenal Artery Embolization

Sponsors

The First Affiliated Hospital of Chengdu Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Strictly follow the clinical guidelines of the International Society of Endocrinology in 2016 to diagnose primary aldosteronism; stop antihypertensive drugs or take antihypertensive drugs that do not affect hormone testing before the PA screening test for 4-6 weeks, and the screening is positive -Aldosterone/renin activity ratio (ARR) >= 38 (pg/ml/pg/ml) for further PA confirmation test (oral sodium load test, saline infusion test, fludrocortisone inhibition test or captopril test); 2. Aged 15 to 75 years, no gender limits; 3. Office blood pressure reached grade 2 or above at least 3 times on different days without taking antihypertensive drugs, with or without hypokalemia; 4. All patients with PA undergo adrenal computed tomography and adrenal venous sampling (AVS) to make the distinction between unilateral and bilateral adrenal disease; 5. The patients were briefed on all current treatment strategy for primary aldosteronism, and they agreed to receive superselective adrenal artery embolization(SAAE).

Exclusion criteria

Exclusion criteria: 1. Severe contrast agent allergy; 2. Stroke, myocardial infarction and stent implantation within 3 months; 3. Renal insufficiency, serum creatinine>176umol/L or estimated glomerular filtration <45ml/(min.1.73m^2); 4. Serious liver diseases, acute infections, autoimmune diseases, various malignant tumors; 5. Pregnant and birth-giving women; 6. Refused to participate or had difficulty cooperating with the study.

Design outcomes

Primary

MeasureTime frame
Office blood pressure;Ambulatory blood pressure;Use of antihypertensive drugs;Use of aldosterone receptor antagonists;Serum potassium;Serum sodium;Plasma renin;Plasma aldosterone;Adrenal CT;

Countries

China

Contacts

Public ContactWang Peijian

The First Affiliated Hospital of Chengdu Medical College

wpjmed@aliyun.com+86 18980718263

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026